Skip to main content

Advertisement

Table 2 Clinical trials in HCC using immune checkpoint inhibitors

From: Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities

Antibody features Antibody name NCT number Status
anti-CTLA4 Ipilimumab NCT03682276,NCT03510871,NCT03222076,NCT03203304 Ongoing
anti-CTLA4 Tremelimumab NCT01853618,NCT02519348,NCT02519348,NCT03298451, NCT02821754,NCT03482102, NCT03638141 Ongoing
NCT01008358 Completed
anti-PD-1 Nivolumab NCT01658878,NCT02576509,NCT03383458, NCT03682276, NCT03071094,NCT03382886, NCT03781960, NCT03033446, NCT03510871, NCT03299946, NCT03059147,NCT03630640, NCT03418922, NCT03655613,NCT02837029, NCT03785210, NCT03695250,NCT03655002, NCT02859324, NCT03439891 Ongoing
anti-PD-1 Pembrolizumab NCT02702401,NCT03062358,NCT03713593,NCT02658019, NCT03753659,NCT03006926,NCT03519997,NCT03337841, NCT03163992,NCT03397654,NCT03316872,NCT03099564, NCT02940496,NCT03419481,NCT03647163,NCT02509507, NCT03211416,NCT03347292,NCT03511222,NCT03095781, NCT03259867,NCT02595866, NCT02432963 Ongoing
anti-PD-1 Tislelizumab NCT03419897, NCT03412773 Ongoing
anti-PD-1 Spartalizumab NCT02988440,NCT02795429, NCT02947165,NCT02325739 Ongoing
anti-PD-1 Camrelizumab NCT02989922,NCT03463876,NCT02942329,NCT03722875, NCT03605706, NCT03793725,NCT03764293, NCT03601598 Ongoing
anti-PD-L1 Durvalumab NCT03298451,NCT03778957,NCT03482102,NCT02519348 NCT03638141,NCT03257761,NCT02821754,NCT02572687, NCT03539822 Ongoing
anti-PD-L1 Avelumab NCT03389126, NCT03289533 Ongoing
anti-PD-L1 Atezolizuamb NCT03170960,NCT03755791, NCT03434379 Ongoing